Trial Outcomes & Findings for Biomarkers in Chemotherapy-Induced Peripheral Neurotoxicity (NCT NCT03348956)

Last Updated: 2024-06-20

Results Overview

EPR Oximetry will measure tissue oxygen levels in the injected foot during 10 minutes of breathing room air, 10 minutes while breathing 100% oxygen, and 10 minutes of room air.

Recruitment status

COMPLETED

Study phase

Target enrollment

7 participants

Primary outcome timeframe

Pre-chemotherapy (Baseline), Mid-chemotherapy (approximately 6 - 8 weeks from Baseline), Post-chemotherapy (approximately 2 - 3 weeks after the participant completed chemotherapy or approximately 14 - 18 weeks from Baseline)

Results posted on

2024-06-20

Participant Flow

Participant milestones

Participant milestones
Measure	EPR Oximetry All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points (pre-exposure, during-exposure or CIPN incidence, and post exposure), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have up to five EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Overall Study STARTED	7
Overall Study Clinical, Electrophysiologic Metrics, and Neuropathy Scales	7
Overall Study COMPLETED	3
Overall Study NOT COMPLETED	4

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	EPR Oximetry n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points (pre-exposure, during-exposure or CIPN incidence, and post exposure), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have up to five EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Age, Categorical <=18 years	0 Participants n=7 Participants
Age, Categorical Between 18 and 65 years	6 Participants n=7 Participants
Age, Categorical >=65 years	1 Participants n=7 Participants
Sex: Female, Male Female	7 Participants n=7 Participants
Sex: Female, Male Male	0 Participants n=7 Participants
Region of Enrollment United States	7 participants n=7 Participants
Body Mass Index (BMI)	30.5 kg/m2 STANDARD_DEVIATION 6.6 • n=7 Participants

PRIMARY outcome

Timeframe: Pre-chemotherapy (Baseline), Mid-chemotherapy (approximately 6 - 8 weeks from Baseline), Post-chemotherapy (approximately 2 - 3 weeks after the participant completed chemotherapy or approximately 14 - 18 weeks from Baseline)

Population: 3 patients underwent testing. 1 patient did not undergo the 100% oxygen condition at the End of Chemo, so there is no data for Mid-Point or recovery for that patient. Data was not gathered for the remaining 4 participants.

EPR Oximetry will measure tissue oxygen levels in the injected foot during 10 minutes of breathing room air, 10 minutes while breathing 100% oxygen, and 10 minutes of room air.

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=3 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen n=3 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) n=3 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Relative Change in % pO2 Mid-Point	12.3 change in % oxygenation Interval -7.0 to 45.0	19 change in % oxygenation Interval -25.0 to 44.0	24 change in % oxygenation Interval 11.0 to 44.0
Relative Change in % pO2 End of Chemo	25.3 change in % oxygenation Interval 20.0 to 32.0	9.5 change in % oxygenation Interval 4.0 to 15.0	42.5 change in % oxygenation Interval 39.0 to 46.0

SECONDARY outcome

Patients will be phenotyped by a neurologic examination before and after exposure to a standard regimen of neurotoxic chemotherapy. MRC scale for muscle strength (0-5) Grade 5: Normal Grade 4: Movement against gravity and resistance Grade 3: Movement against gravity over (almost) the full range Grade 2: Movement of the limb but not against gravity Grade 1: Visible contraction without movement of the limb (not existent for hip flexion) Grade 0: No visible contraction

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Neurologic Examination_ Strength_ Toe Fan Post	4.89 Units on a scale Standard Deviation 0.27	—	—
Neurologic Examination_ Strength_ Toe Fan Pre	5 Units on a scale Standard Deviation 0	—	—
Neurologic Examination_ Strength_ Toe Fan Mid	4.98 Units on a scale Standard Deviation 0.06	—	—

SECONDARY outcome

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Neurologic Examination_ Strength_ Toe Flex Pre	5 Units on a scale Standard Deviation 0	—	—
Neurologic Examination_ Strength_ Toe Flex Mid	4.98 Units on a scale Standard Deviation 0.06	—	—
Neurologic Examination_ Strength_ Toe Flex Post	4.89 Units on a scale Standard Deviation 0.31	—	—

SECONDARY outcome

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Neurologic Examination_ Strength_ Inv Pre	5 Units on a scale Standard Deviation 0	—	—
Neurologic Examination_ Strength_ Inv Mid	4.96 Units on a scale Standard Deviation 0.09	—	—
Neurologic Examination_ Strength_ Inv Post	4.96 Units on a scale Standard Deviation 0.09	—	—

SECONDARY outcome

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Neurologic Examination_ Strength_ Ev Pre	5 Units on a scale Standard Deviation 0	—	—
Neurologic Examination_ Strength_ Ev Mid	4.96 Units on a scale Standard Deviation 0.09	—	—
Neurologic Examination_ Strength_ Ev Post	4.96 Units on a scale Standard Deviation 0.09	—	—

SECONDARY outcome

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Neurologic Examination_ Strength_ ADF Pre	5 Units on a scale Standard Deviation 0	—	—
Neurologic Examination_ Strength_ ADF Mid	5 Units on a scale Standard Deviation 0	—	—
Neurologic Examination_ Strength_ ADF Post	5 Units on a scale Standard Deviation 0	—	—

SECONDARY outcome

Patients will be phenotyped by a neurologic examination before and after exposure to a standard regimen of neurotoxic chemotherapy. The position of the intersect is recorded on an arbitrary scale from 0 to 8 on a Rydel-Seiffer tuning fork once the subject is no longer perceiving vibration. The higher the number, the better the vibratory sense.

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Neurologic Examination_ Vibration Sense_Toe Post	4.53 Units on a scale Standard Deviation 2.09	—	—
Neurologic Examination_ Vibration Sense_Toe Pre	6.71 Units on a scale Standard Deviation 0.82	—	—
Neurologic Examination_ Vibration Sense_Toe Mid	4.66 Units on a scale Standard Deviation 3.10	—	—

SECONDARY outcome

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Neurologic Examination_ Vibration Sense_MM Pre	6.73 Units on a scale Standard Deviation 0.80	—	—
Neurologic Examination_ Vibration Sense_MM Post	5.78 Units on a scale Standard Deviation 1.20	—	—
Neurologic Examination_ Vibration Sense_MM Mid	6.44 Units on a scale Standard Deviation 1.01	—	—

SECONDARY outcome

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Neurologic Examination_ Vibration Sense_Knee Pre	6.96 Units on a scale Standard Deviation 0.86	—	—
Neurologic Examination_ Vibration Sense_Knee Mid	7 Units on a scale Standard Deviation 0.98	—	—
Neurologic Examination_ Vibration Sense_Knee Post	6.10 Units on a scale Standard Deviation 0.68	—	—

SECONDARY outcome

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Neurologic Examination_ Vibration Sense_DIP2 Pre	7.82 Units on a scale Standard Deviation 0.46	—	—
Neurologic Examination_ Vibration Sense_DIP2 Mid	7.78 Units on a scale Standard Deviation 0.57	—	—
Neurologic Examination_ Vibration Sense_DIP2 Post	7.53 Units on a scale Standard Deviation 0.66	—	—

SECONDARY outcome

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Neurologic Examination_ Vibration Sense_DIP5 Pre	7.72 Units on a scale Standard Deviation 0.61	—	—
Neurologic Examination_ Vibration Sense_DIP5 Mid	7.76 Units on a scale Standard Deviation 0.57	—	—
Neurologic Examination_ Vibration Sense_DIP5 Post	7.60 Units on a scale Standard Deviation 0.59	—	—

SECONDARY outcome

Patients will be phenotyped by a neurologic examination before and after exposure to a standard regimen of neurotoxic chemotherapy. REFLEX SCALE for Deep Tendon Reflexes (DTRs) The score ranges from 0 - 9, where 0 is no reflex response (areflexia)/always abnormal, greater than 1 and less than 3 is normal, and 9 is a tap that elicits a repeating reflex (clonus)/always abnormal.

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Neurologic Examination_ Deep Tendon Reflexes _ Biceps Pre	4.42 Units on a scale Standard Deviation 0.51	—	—
Neurologic Examination_ Deep Tendon Reflexes _ Biceps Mid	3.28 Units on a scale Standard Deviation 1.89	—	—
Neurologic Examination_ Deep Tendon Reflexes _ Biceps Post	2.14 Units on a scale Standard Deviation 1.61	—	—

SECONDARY outcome

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Neurologic Examination_ Deep Tendon Reflexes _ Triceps Pre	4.14 Units on a scale Standard Deviation 1.02	—	—
Neurologic Examination_ Deep Tendon Reflexes _ Triceps Mid	3.14 Units on a scale Standard Deviation 1.74	—	—
Neurologic Examination_ Deep Tendon Reflexes _ Triceps Post	2.57 Units on a scale Standard Deviation 1.78	—	—

SECONDARY outcome

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Neurologic Examination_ Deep Tendon Reflexes _ BR Pre	4.21 Units on a scale Standard Deviation 0.57	—	—
Neurologic Examination_ Deep Tendon Reflexes _ BR Mid	3.28 Units on a scale Standard Deviation 1.54	—	—
Neurologic Examination_ Deep Tendon Reflexes _ BR Post	1.92 Units on a scale Standard Deviation 1.32	—	—

SECONDARY outcome

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Neurologic Examination_ Deep Tendon Reflexes _ Patella Pre	4 units on a scale Standard Deviation 0.67	—	—
Neurologic Examination_ Deep Tendon Reflexes _ Patella Mid	3.28 units on a scale Standard Deviation 1.13	—	—
Neurologic Examination_ Deep Tendon Reflexes _ Patella Post	2.71 units on a scale Standard Deviation 1.63	—	—

SECONDARY outcome

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Neurologic Examination_ Deep Tendon Reflexes _ Achilles Pre	4.14 units on a scale Standard Deviation 0.77	—	—
Neurologic Examination_ Deep Tendon Reflexes _ Achilles Mid	1.57 units on a scale Standard Deviation 1.78	—	—
Neurologic Examination_ Deep Tendon Reflexes _ Achilles Post	1 units on a scale Standard Deviation 1.35	—	—

SECONDARY outcome

Population: Pre- is prior to chemotherapy exposure Mid- is midway through chemotherapy regimen Post- is one week or more after chemotherapy completion

Electrophysiologic testing will measure nerve conduction amplitude in patients before and after exposure to a standard regimen of neurotoxic chemotherapy.

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Mean Nerve Conduction Metrics (Amplitude)_DORSAL SURAL Pre	6.2 uV Standard Deviation 8.8	—	—
Mean Nerve Conduction Metrics (Amplitude)_DORSAL SURAL Mid	6.3 uV Standard Deviation 7.7	—	—
Mean Nerve Conduction Metrics (Amplitude)_DORSAL SURAL Post	3.5 uV Standard Deviation 4.7	—	—

SECONDARY outcome

Population: Pre- is prior to chemotherapy exposure Mid- is midway through chemotherapy regimen Post- is one week or more after chemotherapy completion

Electrophysiologic testing will measure nerve conduction amplitude in patients before and after exposure to a standard regimen of neurotoxic chemotherapy.

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Change in Nerve Conduction Metrics (Amplitude)_MED PLANTAR Pre	7.5 uV Standard Deviation 7.2	—	—
Change in Nerve Conduction Metrics (Amplitude)_MED PLANTAR Mid	6.4 uV Standard Deviation 7.1	—	—
Change in Nerve Conduction Metrics (Amplitude)_MED PLANTAR Post	5.7 uV Standard Deviation 6.9	—	—

SECONDARY outcome

Population: Pre- is prior to chemotherapy exposure Mid- is midway through chemotherapy regimen Post- is one week or more after chemotherapy completion

Electrophysiologic testing will measure nerve conduction amplitude in patients before and after exposure to a standard regimen of neurotoxic chemotherapy.

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Change in Nerve Conduction Metrics (Amplitude)_SURAL Pre	21.9 uV Standard Deviation 13.1	—	—
Change in Nerve Conduction Metrics (Amplitude)_SURAL Mid	16.6 uV Standard Deviation 7.0	—	—
Change in Nerve Conduction Metrics (Amplitude)_SURAL Post	19.5 uV Standard Deviation 13.4	—	—

SECONDARY outcome

Population: Pre-Mid- is prior to chemotherapy exposure Pre-Post- is one week or more after chemotherapy completion

Electrophysiologic testing will measure nerve conduction amplitude in patients before and after exposure to a standard regimen of neurotoxic chemotherapy. The outcome measure is reporting the average of the differences in amplitudes Pre-Mid and Pre-Post exposure (for example, the change from Pre and Mid is calculated, and then the change across all participants is averaged).

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Mean of the Difference in Nerve Conduction Amplitudes Between Pre-Mid and Pre-Post exposure_Dorsal Sural Pre-Mid-Mean	-0.47 uV Interval -2.3 to 1.0	—	—
Mean of the Difference in Nerve Conduction Amplitudes Between Pre-Mid and Pre-Post exposure_Dorsal Sural Pre-Post-Mean	-3.87 uV Interval -10.7 to 0.0	—	—

SECONDARY outcome

Population: Pre-Mid- is prior to chemotherapy exposure Pre-Post- is one week or more after chemotherapy completion

Electrophysiologic testing will measure nerve conduction amplitude in patients before and after exposure to a standard regimen of neurotoxic chemotherapy.

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Change in Nerve Conduction/Mixed Nerve Amplitudes _Medial Plantar Pre-Mid-Mean	-1.0 uV Interval -7.8 to 3.6	—	—
Change in Nerve Conduction/Mixed Nerve Amplitudes _Medial Plantar Pre-Post-Mean	-1.7 uV Interval -13.7 to 3.3	—	—

SECONDARY outcome

Population: Pre-Mid- is prior to chemotherapy exposure Pre-Post- is one week or more after chemotherapy completion

Electrophysiologic testing will measure nerve conduction amplitude in patients before and after exposure to a standard regimen of neurotoxic chemotherapy.

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Change in Nerve Conduction/Mixed Nerve Amplitudes _Sural Pre-Mid-Mean	-5.2 uV Interval -24.3 to 6.5	—	—
Change in Nerve Conduction/Mixed Nerve Amplitudes _Sural Pre-Post-Mean	-2.3 uV Interval -9.5 to 6.7	—	—

SECONDARY outcome

Population: Pre- is prior to chemotherapy exposure Mid- is midway through chemotherapy regimen Post- is one week or more after chemotherapy completion

Electrophysiologic testing will measure nerve conduction amplitude in patients before and after exposure to a standard regimen of neurotoxic chemotherapy.

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Change in Nerve Conduction_Motor_ (Amplitude)_Peron-EDB Pre	4.6 mV Standard Deviation 1.1	—	—
Change in Nerve Conduction_Motor_ (Amplitude)_Peron-EDB Mid	3.4 mV Standard Deviation 1.9	—	—
Change in Nerve Conduction_Motor_ (Amplitude)_Peron-EDB Post	3.4 mV Standard Deviation 2.7	—	—

SECONDARY outcome

Population: Pre- is prior to chemotherapy exposure Mid- is midway through chemotherapy regimen Post- is one week or more after chemotherapy completion

Electrophysiologic testing will measure nerve conduction amplitude in patients before and after exposure to a standard regimen of neurotoxic chemotherapy.

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Change in Nerve Conduction_Motor_ (Amplitude)_Peron-TA Pre	5.2 mV Standard Deviation 1.4	—	—
Change in Nerve Conduction_Motor_ (Amplitude)_Peron-TA Mid	5.1 mV Standard Deviation 1.3	—	—
Change in Nerve Conduction_Motor_ (Amplitude)_Peron-TA Post	5.1 mV Standard Deviation 1.9	—	—

SECONDARY outcome

Population: Pre- is prior to chemotherapy exposure Mid- is midway through chemotherapy regimen Post- is one week or more after chemotherapy completion

Electrophysiologic testing will measure nerve conduction amplitude in patients before and after exposure to a standard regimen of neurotoxic chemotherapy.

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Change in Nerve Conduction_Motor_ (Amplitude)_Tibial-AH Pre	9.2 mV Standard Deviation 3.9	—	—
Change in Nerve Conduction_Motor_ (Amplitude)_Tibial-AH Mid	9.0 mV Standard Deviation 5.7	—	—
Change in Nerve Conduction_Motor_ (Amplitude)_Tibial-AH Post	10.1 mV Standard Deviation 6.8	—	—

SECONDARY outcome

Population: For the dorsal sural sensory nerve, a change in mean velocity pre-chemotherapy to mid-chemotherapy is reported as well as the change in mean velocity for pre-chemotherapy to post-chemotherapy

Electrophysiologic testing will measure nerve conduction velocity in patients before and after exposure to a standard regimen of neurotoxic chemotherapy.

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Nerve Conduction Metrics as Measured by Mean Change (Velocity) for Peroneal CMAP AMP, EDB Pre-Mid	-1.1 m/s Interval -3.9 to 0.5	—	—
Nerve Conduction Metrics as Measured by Mean Change (Velocity) for Peroneal CMAP AMP, EDB Pre-Post	-1.4 m/s Interval -4.6 to 0.7	—	—

SECONDARY outcome

Electrophysiologic testing will measure nerve conduction velocity in patients before and after exposure to a standard regimen of neurotoxic chemotherapy.

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Nerve Conduction Metrics as Measured by Mean Change (Velocity) for Peroneal CMAP, AT Pre-Mid	0 m/s Interval -1.6 to 3.8	—	—
Nerve Conduction Metrics as Measured by Mean Change (Velocity) for Peroneal CMAP, AT Pre-Post	0 m/s Interval -2.8 to 5.5	—	—

SECONDARY outcome

Electrophysiologic testing will measure nerve conduction velocity in patients before and after exposure to a standard regimen of neurotoxic chemotherapy.

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Nerve Conduction Metrics as Measured by Mean Change (Velocity) for Tibial CMAP, AH Pre-Mid	-0.2 m/s Interval -4.4 to 3.3	—	—
Nerve Conduction Metrics as Measured by Mean Change (Velocity) for Tibial CMAP, AH Pre-Post	0.9 m/s Interval -1.6 to 7.3	—	—

SECONDARY outcome

Electrophysiologic testing will measure nerve conduction velocity in patients before and after exposure to a standard regimen of neurotoxic chemotherapy.

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Nerve Conduction Metrics as Measured by Mean Change (Velocity) for Dorsal Sural CV Pre-Mid	1.8 m/s Interval -4.0 to 13.8	—	—
Nerve Conduction Metrics as Measured by Mean Change (Velocity) for Dorsal Sural CV Pre-Post	-1.5 m/s Interval -6.0 to 2.0	—	—

SECONDARY outcome

Population: For the Med Plantar sensory nerve, a change in mean velocity pre-chemotherapy to mid-chemotherapy is reported as well as the change in mean velocity for pre-chemotherapy to post-chemotherapy

Electrophysiologic testing will measure nerve conduction velocity in patients before and after exposure to a standard regimen of neurotoxic chemotherapy.

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Nerve Conduction Metrics as Measured by Mean Change (Velocity) for Med Plantar CV Pre-Mid	-1.2 m/s Interval -9.6 to 4.3	—	—
Nerve Conduction Metrics as Measured by Mean Change (Velocity) for Med Plantar CV Pre-Post	-3.5 m/s Interval -18.7 to 3.7	—	—

SECONDARY outcome

Population: For the Sural sensory nerve, a change in mean velocity pre-chemotherapy to mid-chemotherapy is reported as well as the change in mean velocity for pre-chemotherapy to post-chemotherapy

Electrophysiologic testing will measure nerve conduction velocity in patients before and after exposure to a standard regimen of neurotoxic chemotherapy.

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Nerve Conduction Metrics as Measured by Mean Change (Velocity) for Sural CV Pre-Mid	2.7 m/s Interval -5.5 to 11.0	—	—
Nerve Conduction Metrics as Measured by Mean Change (Velocity) for Sural CV Pre-Post	0.3 m/s Interval -10.6 to 9.4	—	—

SECONDARY outcome

Population: For the Peroneal CV, distal sensory nerve, a change in mean velocity pre-chemotherapy to mid-chemotherapy is reported as well as the change in mean velocity for pre-chemotherapy to post-chemotherapy

Electrophysiologic testing will measure nerve conduction velocity in patients before and after exposure to a standard regimen of neurotoxic chemotherapy.

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Nerve Conduction Metrics as Measured by Mean Change (Velocity) for Peroneal CV, Distal Pre-Mid	1.6 m/s Interval -2.0 to 4.5	—	—
Nerve Conduction Metrics as Measured by Mean Change (Velocity) for Peroneal CV, Distal Pre-Post	-2.2 m/s Interval -8.3 to 4.1	—	—

SECONDARY outcome

Population: Pre- is prior to chemotherapy exposure Mid- is midway through chemotherapy regimen Post- is one week or more after chemotherapy completion.

Neuropathy-Specific Quality of Life scale measuring Positive Affect and Well Being The range in score is 23 to 115, with a low score indicating a less positive affect and well-being

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Mean Score of Neuro-Quality of Life - Positive Affect and Well-Being Scale Pre	93.9 score on a scale Standard Deviation 21.5	—	—
Mean Score of Neuro-Quality of Life - Positive Affect and Well-Being Scale Mid	96.3 score on a scale Standard Deviation 17.4	—	—
Mean Score of Neuro-Quality of Life - Positive Affect and Well-Being Scale Post	100.6 score on a scale Standard Deviation 17.1	—	—

SECONDARY outcome

Population: Pre- is prior to chemotherapy exposure Mid- is midway through chemotherapy regimen Post- is one week or more after chemotherapy completion

Neuropathy-Specific Quality of Life scale measuring Satisfaction with Social Roles and Activities The range in scores is 47 to 235, with a lower score indicating less satisfaction with social roles and activities

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Mean Score of Neuro-Quality of Life - Satisfaction With Social Roles and Activities Scale Post	187.6 score on a scale Standard Deviation 50.0	—	—
Mean Score of Neuro-Quality of Life - Satisfaction With Social Roles and Activities Scale Pre	172.9 score on a scale Standard Deviation 46.4	—	—
Mean Score of Neuro-Quality of Life - Satisfaction With Social Roles and Activities Scale Mid	187.1 score on a scale Standard Deviation 33.5	—	—

SECONDARY outcome

Population: Pre- is prior to chemotherapy exposure Mid- is midway through chemotherapy regimen Post- is one week or more after chemotherapy completion

Neuropathy-Specific Quality of Life scale measuring Lower Extremity Function (Mobility) The range in scores is 19 to 95, with a lower score indicating more difficulty with lower extremity function

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Mean Score of Neuro-Quality of Life - Lower Extremity Function (Mobility) Scale Pre	89.1 score on a scale Standard Deviation 10.1	—	—
Mean Score of Neuro-Quality of Life - Lower Extremity Function (Mobility) Scale Mid	90.6 score on a scale Standard Deviation 7.1	—	—
Mean Score of Neuro-Quality of Life - Lower Extremity Function (Mobility) Scale Post	91.4 score on a scale Standard Deviation 5.9	—	—

SECONDARY outcome

Population: Pre- is prior to chemotherapy exposure Mid- is midway through chemotherapy regimen Post- is one week or more after chemotherapy completion

Neuropathy-Specific Quality of Life scale measuring Upper Extremity Function (Fine Motor, Activities of Daily Living) The range in scores is 20 to 100, with a low score indicating more difficulty with upper extremity function

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Mean Score of Neuro-Quality of Life - Upper Extremity Function (Fine Motor, Activities of Daily Living) Scale Pre	97.0 score on a scale Standard Deviation 5.5	—	—
Mean Score of Neuro-Quality of Life - Upper Extremity Function (Fine Motor, Activities of Daily Living) Scale Mid	99.3 score on a scale Standard Deviation 1.5	—	—
Mean Score of Neuro-Quality of Life - Upper Extremity Function (Fine Motor, Activities of Daily Living) Scale Post	97.9 score on a scale Standard Deviation 4.4	—	—

SECONDARY outcome

Population: Pre- is prior to chemotherapy exposure Mid- is midway through chemotherapy regimen Post- is one week or more after chemotherapy completion

Neuropathy Total Symptom Score questionnaire with 6 questions The range is scores is 0 to 22 with a higher score indicating worse symptoms

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Mean Score of The Neuropathy Total Symptom Score-6 Questionnaire Pre	0.3 score on a scale Standard Deviation 0.5	—	—
Mean Score of The Neuropathy Total Symptom Score-6 Questionnaire Mid	2.2 score on a scale Standard Deviation 1.8	—	—
Mean Score of The Neuropathy Total Symptom Score-6 Questionnaire Post	3.1 score on a scale Standard Deviation 3.1	—	—

SECONDARY outcome

Population: Pre- is prior to chemotherapy exposure Mid- is midway through chemotherapy regimen Post- is one week or more after chemotherapy completion

Toronto Clinical Neuropathy Scoring System The range in scores is 0 to 19 with higher scores indicating worse neuropathy

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Mean Score of Toronto Clinical Neuropathy Scoring System Pre	2.1 score on a scale Standard Deviation 2.0	—	—
Mean Score of Toronto Clinical Neuropathy Scoring System Mid	5.3 score on a scale Standard Deviation 3.4	—	—
Mean Score of Toronto Clinical Neuropathy Scoring System Post	5.0 score on a scale Standard Deviation 3.7	—	—

SECONDARY outcome

Population: Pre- is prior to chemotherapy exposure Mid- is midway through chemotherapy regimen Post- is one week or more after chemotherapy completion

National Cancer Insitute - Common Toxicity Criteria The range in scores is 0 to 5, with higher scores indicating worse toxicity

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Mean Score of National Cancer Institute - Common Toxicity Criteria Pre	0.3 score on a scale Standard Deviation 0.8	—	—
Mean Score of National Cancer Institute - Common Toxicity Criteria Mid	0.7 score on a scale Standard Deviation 1.0	—	—
Mean Score of National Cancer Institute - Common Toxicity Criteria Post	1.4 score on a scale Standard Deviation 0.8	—	—

SECONDARY outcome

Population: Pre- is prior to chemotherapy exposure Mid- is midway through chemotherapy regimen Post- is one week or more after chemotherapy completion

Total Neuropathy score The range in scores is 0 to 40, with higher scores indicating worse neuropathy

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Mean Score of Total Neuropathy Scores Pre	1.3 score on a scale Standard Deviation 1.1	—	—
Mean Score of Total Neuropathy Scores Mid	6.0 score on a scale Standard Deviation 5.0	—	—
Mean Score of Total Neuropathy Scores Post	8.1 score on a scale Standard Deviation 6.2	—	—

SECONDARY outcome

Population: Pre- is prior to chemotherapy exposure Mid- is midway through chemotherapy regimen Post- is one week or more after chemotherapy completion

Survey of Autonomic Symptoms, questions in Column B The range in scores is 0 to 55 for women and 0 to 60 for men, with higher scores indicating more bothersome symptoms

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Mean Score of Survey of Autonomic Symptoms, Column B Pre	5.9 score on a scale Standard Deviation 3.7	—	—
Mean Score of Survey of Autonomic Symptoms, Column B Mid	6.9 score on a scale Standard Deviation 4.9	—	—
Mean Score of Survey of Autonomic Symptoms, Column B Post	5.2 score on a scale Standard Deviation 3.9	—	—

SECONDARY outcome

Population: Pre- is prior to chemotherapy exposure Mid- is midway through chemotherapy regimen Post- is one week or more after chemotherapy completion

McGill Visual Analog Scale for Pain The range in scores is 0 to 100, with 0 indicting "No pain" and 100 indicating "Worst pain possible"

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Mean Score of McGill Pain Visual Analog Scale Pre	21.0 score on a scale Standard Deviation 23.8	—	—
Mean Score of McGill Pain Visual Analog Scale Mid	27.9 score on a scale Standard Deviation 25.5	—	—
Mean Score of McGill Pain Visual Analog Scale Post	27.3 score on a scale Standard Deviation 30.9	—	—

SECONDARY outcome

Population: Pre- is prior to chemotherapy exposure Mid- is midway through chemotherapy regimen Post- is one week or more after chemotherapy completion

Short Form McGill Pain Questionnaire The range in scores is 0 to 15, with higher scores indicating worse pain

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Mean Scores of Short Form McGill Pain Questionnaire Pre	3.3 score on a scale Standard Deviation 4.0	—	—
Mean Scores of Short Form McGill Pain Questionnaire Mid	2.4 score on a scale Standard Deviation 2.1	—	—
Mean Scores of Short Form McGill Pain Questionnaire Post	2.3 score on a scale Standard Deviation 1.9	—	—

SECONDARY outcome

Population: Pre- is prior to chemotherapy exposure Mid- is midway through chemotherapy regimen Post- is one week or more after chemotherapy completion

Survey of Autonomic Symptoms, questions in column A The range in scores is 0 to 11 for women and 0 to 12 for men, with higher scores indicating more symptoms

Outcome measures

Outcome measures
Measure	Relative % pO2 Change From Baseline While Breathing Room Air n=7 Participants All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing 100% Oxygen All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.	Relative % pO2 Change From Baseline While Breathing Room Air (Recovery) All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points: pre-exposure (Baseline), during-exposure or CIPN incidence (Mid-Point), and post exposure (End of chemo), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Mean Score of Survey of Autonomic Symptoms, Column A Post	2.0 score on a scale Standard Deviation 1.4	—	—
Mean Score of Survey of Autonomic Symptoms, Column A Pre	2.4 score on a scale Standard Deviation 1.1	—	—
Mean Score of Survey of Autonomic Symptoms, Column A Mid	2.3 score on a scale Standard Deviation 0.8	—	—

SECONDARY outcome

Timeframe: 1 year

Population: Samples were never gathered due to no participants enrolled after protocol was amended to include the collection of serum NF-L.

Changes in serum NFL levels over the course of chemotherapy will be monitored to determine if NFL can be used as a biomarker for axonal damage in patients who develop CIPN. NFL will be measured at baseline, before each round of chemotherapy and at the completion of chemotherapy. Changes in NFL will be compared between patients who develop CIPN and those that do not.

Outcome measures

Outcome data not reported

Adverse Events

EPR Oximetry

Serious events: 0 serious events

Other events: 6 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure	EPR Oximetry n=7 participants at risk All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points (pre-exposure, during-exposure or CIPN incidence, and post exposure), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing. EPR Oximetry: Subjects will have up to five EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
General disorders Dysphagia	28.6% 2/7 • Number of events 2 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders High WBC w/o infection	42.9% 3/7 • Number of events 3 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Thrush on tongue	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Low K+ Lab	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Diverticulitis	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Shortness of breath	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders left ankle swelling-occasional	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Pain during urination	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Worsening Appetite	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
Vascular disorders Erythema	28.6% 2/7 • Number of events 2 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Nausea	42.9% 3/7 • Number of events 3 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Increased symptoms of reflux	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Abnormal Lab Values	28.6% 2/7 • Number of events 2 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
Gastrointestinal disorders Diarrhea	28.6% 2/7 • Number of events 2 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders High LFT's	28.6% 2/7 • Number of events 2 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Increased Fatigue	42.9% 3/7 • Number of events 3 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Soreness in both walls along MRM incision	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
Nervous system disorders CIPN	71.4% 5/7 • Number of events 5 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Redness/Itchy on scalp	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Cramping in calves- severe	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Discomfort in anterior aspect of shins	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Decreased Dexterity	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Increased unsteadiness	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Chest Pain	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Indigestion	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Headache	28.6% 2/7 • Number of events 2 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Sore Throat due to Nocturnal Epistaxis	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Alopecia	42.9% 3/7 • Number of events 3 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Anemia-Mild	28.6% 2/7 • Number of events 2 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Knee Pain	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Pain up to hip from knee	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Shingles	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Cellulitis	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Bloating	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Dry Mouth	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Hyperhidrosis	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Brief periods of heart pounding	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Aches, Cramps and Spasms	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Sore on tip of tongue	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Brief burning sensation on chest, back, and legs	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Low grade fever	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Ecchymosis	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Bilateral ankle swelling	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Myalgia	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Cytopenia	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Discomfort at Injection Site	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Right Hip/Lower back pain	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Myalgias	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Fever	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Mild Cough	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Mild Anemia	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Arthralgias	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Dysgeusia	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Acute Pharyngitis	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Pain at injection site	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Purple Hematoma at injection site	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Rash-under Arm Pit	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Redness along hands and wrists	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Mouth Sore	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Tearing of eyes	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.
General disorders Allergic Reaction	14.3% 1/7 • Number of events 1 • Adverse events will be reported from the initiation of any study procedures to the end of the study treatment follow-up. Adverse events were collected from Baseline through 15 - 18 weeks after chemotherapy.

Additional Information

Victoria Lawson

Dartmouth Hitchcock Medical Center

Phone: (603) 650-5104

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place